Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | AHR | P35869 | 2/20 | 0.53 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | CCR8 | P51685 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL668615 | 0.84 | AHR (0.53) | ALDH1A1HSD17B10AHRCCR8LMNA | |
| SCHEMBL12338439 | 0.78 | ALDH1A1 (0.65) | ALDH1A1HSD17B10AHRCCR8HPGD | |
| SCHEMBL10587891 | 0.78 | ALDH1A1 (0.55) | ALDH1A1HSD17B10AHRCCR8GPR84 | |
| SCHEMBL5636806 | 0.78 | ALDH1A1 (1.00) | ALDH1A1HSD17B10AHRDAOCCR8 | |
| SCHEMBL30544111 | 0.78 | ALDH1A1 (1.00) | ALDH1A1HSD17B10AHRDAOCCR8 | |
| SCHEMBL12338438 | 0.76 | ALDH1A1 (0.63) | ALDH1A1HSD17B10AHRCCR8HPGD | |
| SCHEMBL12663392 | 0.76 | ALDH1A1 (0.63) | ALDH1A1HSD17B10CCR8LMNAKMT2A | |
| SCHEMBL8534518 | 0.76 | ALDH1A1 (0.63) | ALDH1A1HSD17B10CCR8KMT2A | |
| SCHEMBL13512629 | 0.76 | ALDH1A1 (0.63) | ALDH1A1HSD17B10AHRCCR8LMNA | |
| SCHEMBL9400251 | 0.76 | HSD17B10 (1.00) | ALDH1A1HSD17B10CCR8HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503439-B2 | Heteroaryl compounds for the treatment of pain | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-23 | — | — | US | disclosed |
| US-20230373925-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-23 | — | — | US | disclosed |
| CN-105461709-B | Substituted urea derivatives and their use in medicine | 广东东阳光药业有限公司 | 2020-01-21 | — | — | CN | disclosed |
| WO-2017198196-A1 | QUINOLINE DERIVATIVE HAVING ANTI-TUMOR ACTIVITY | 王子厚 | 2017-11-23 | — | — | WO | disclosed |
| US-7973164-B2 | Quinoline derivatives | ASTRAZENECA AB (SE) | 2011-07-05 | — | — | US | disclosed |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090042910-A1 | QUINOLINE DERIVATIVES FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| EP-1994028-A1 | QUINOLINE DERIVATIVES FOR TREATING CANCER | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| EP-1994025-A1 | QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007099335-A1 | QUINOLINE DERIVATIVES FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007099326-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |
| EP-0990647-B1 | PROCESS FOR PRODUCING QUINOLONE DERIVATIVES | KIRIN BREWERY (JP) | 2003-07-02 | — | — | EP | disclosed |
| US-6187926-B1 | REACTING ORTHO-AMINOACETOPHENONE DERIVATIVE WITH FORMIC ACID ESTER IN APROTIC SOLVENT IN PRESENCE OF BASE, ADDING PROTIC SOLVENT TO REACTION MIXTURE | KIRIN BEER KABUSHIKI KAISHA (JP) | 2001-02-13 | — | — | US | disclosed |
| EP-0990647-A1 | PROCESS FOR PRODUCING QUINOLONE DERIVATIVES | KIRIN BEER KABUSHIKI KAISHA (JP) | 2000-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373925-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | TRPV1, SCN3A, KCNN3 | ALDH1A1 1762/4885HSD17B10 919/4885AHR 2604/4885 |
| US-12503439-B2 | Heteroaryl compounds for the treatment of pain | TRPV1, SCN3A, KCNN3 | ALDH1A1 1762/4885HSD17B10 919/4885AHR 2604/4885 |
| US-20090042910-A1 | QUINOLINE DERIVATIVES FOR TREATING CANCER | RECQL, NQO2, NRAS | ALDH1A1 932/4885HSD17B10 3993/4885AHR 2622/4885 |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, CCNA1 | ALDH1A1 887/4885HSD17B10 3699/4885AHR 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.